Related Experiment Video
Updated: Sep 7, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Giant cell myocarditis after first dose of BNT162b2 - a case report
Valentin G Hirsch1, Sven Schallhorn1, Carolin Zwadlo1
1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
None:
Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.
Related Concept Videos
Myocarditis I: Introduction
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy

